Quick Answer
CATALYST PHARMACEUTICALS, INC. reported R&D Expense of $12.71 million for fiscal year 2025.
CATALYST PHARMACEUTICALS, INC. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $12.71M | +0.5% |
| 2024 | $12.65M | -86.4% |
| 2023 | $93.15M | +370.7% |
| 2022 | $19.79M | +16.8% |
| 2021 | $16.94M | +2.7% |
| 2020 | $16.50M | -12.5% |
| 2019 | $18.84M | -5.4% |
| 2018 | $19.92M | +75.1% |
| 2017 | $11.38M | +0.0% |
| 2016 | $11.37M | -3.7% |
| 2015 | $11.80M | +16.6% |
| 2014 | $10.12M | +25.0% |
| 2013 | $8.10M | +204.4% |
| 2012 | $2.66M | -21.4% |
| 2011 | $3.38M | +46.7% |
| 2010 | $2.31M | -54.7% |
| 2009 | $5.10M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.66M | -19.1% | -39.0% |
| June 30, 2025 | $4.36M | +46.0% | +12.1% |
| March 31, 2025 | $3.89M | +50.6% | +18.4% |
| September 30, 2024 | $3.28M | -96.1% | +10.0% |
| June 30, 2024 | $2.98M | -24.5% | +15.7% |
| March 31, 2024 | $2.58M | -27.5% | -96.9% |
| September 30, 2023 | $83.66M | +906.8% | +2015.9% |
| June 30, 2023 | $3.95M | -0.7% | +11.0% |
- CATALYST PHARMACEUTICALS, INC. showed an increase of +0.5% in R&D Expense compared to the prior fiscal year.
- Over the 2009–2025 period, CATALYST PHARMACEUTICALS, INC.’s r&d expense has grown by 149.3% (from $5.10 million to $12.71 million).
- The most recent figure is from CATALYST PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: